



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

APR 20 1999

Re: Gonal-F
Docket No.: 98E-0488

The Honorable Q. Todd Dickinson
Assistant Secretary of Commerce and
Commissioner of Patents and Trademarks
Box Pat. Ext.
Assistant Commissioner for Patents
Washington, DC 20231

Dear Commissioner Dickinson:

This is in regard to the application for patent term extension for U.S. Patent No. 5,156,957, filed by Genzyme Corporation, under 35 U.S.C. § 156 et seq. We have reviewed the dates contained in the application and have determined the regulatory review period for Gonal-F, the human drug product claimed by the patent.

The total length of the regulatory review period for Gonal-F is 2,044 days. Of this time, 569 days occurred during the testing phase and 1,475 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under subsection 505(i) of the Federal Food, Drug, and Cosmetic Act involving this drug product became effective: February 26, 1992.

FDA has verified the applicant's claim that the date the Investigational New Drug application became effective was on February 26, 1992

2. The date the application was initially submitted with respect to the human drug product under section 505 of the Federal Food, Drug, and Cosmetic Act: September 16, 1993.

FDA has verified the applicant's claim that the new drug application (NDA) for Gonal-F (NDA 20-378) was initially submitted on September 16, 1993.

3. The date the application was approved: September 29, 1997.

FDA has verified the applicant's claim that NDA 20-378 was approved on September 29, 1997.


98E-0488

LET4

This determination of the regulatory review period by FDA does not take into account the effective date of the patent, nor does it exclude one-half of the testing phase as required by 35 U.S.C. § 156(c)(2).

Please let me know if we can be of further assistance.

Sincerely yours,

A handwritten signature in cursive script that reads "Thomas J. McGinnis".

Thomas J. McGinnis, R.Ph.
Deputy Associate Commissioner
for Health Affairs

cc: Roger L. Browdy
BROWDY AND NIEMARK
Suite 300
419 Seventh Street, N.W.
Washington, DC 20004-2299

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service
Food and Drug Administration

0149 '99 APR 22 P1:41
Memorandum

Date: **APR 20 1999**

From: **Brian J. Malkin, Associate Director for Patents and Hearings
Health Assessment Policy Staff (HFY-20)**

Subject: **Patent Term Restoration Application
for Gonal-F**

To: **Dockets Management (HFA-305)**

Attached is a letter to the Patent Term Office for the above mentioned human drug product under the Docket Number **98E-0488** stating that this particular patent is eligible for regulatory review. The Patent Number is **5,156,957**. Please place this recent correspondence in the appropriate file.

If you have any questions, please contact me at 827-6620. Thank you for your assistance.

DATE: APR 20 1999
TO: Sabrina Crisp, Regulations Policy and Management Staff, HF-26
From: Brian J. Malkin, Associate Director for Patents and Hearings, HFY-20
RE: Federal Register Notice Information for Gonal-F
Docket No. 98E-0488, FRDTS# OC9972

Attached is a FR Notice for the human drug product, Gonal-F. This document has been internally reviewed and cleared by OHA.

Please call me if you have any questions. My number is 827-6620 (Rm. 15-22).

Thank you for your assistance.